Twist Bioscience Corporation
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Twist Bioscience Corporation (Nasdaq: TWST), a synthetic biology company founded in 2013 and headquartered in South San Francisco, California, develops and commercializes a proprietary silicon-based platform for high-throughput DNA synthesis that industrializes the engineering of biology; the company manufactures and sells synthetic DNA-based products including synthetic genes and gene fragments for academic research, drug discovery, industrial chemicals, and synthetic biology applications; oligonucleotide pools for CRISPR screening, antibody discovery, and mutagenesis studies; next-generation sequencing (NGS) target enrichment solutions such as customizable panels for clinical diagnostics, cancer research, human genetics, and agrigenomics; biopharma solutions encompassing antibody discovery libraries, optimization services, and integrated discovery platforms; and exploratory DNA data storage solutions offering ultra-high density archival capabilities. Twist operates highly automated manufacturing facilities in South San Francisco, California, and Wilson, North Carolina, serving approximately 2,200 customers across healthcare, agriculture, industrial chemicals, and academic research sectors with global reach in the Americas, EMEA, and Asia-Pacific; the company generates revenue through its e-commerce platform with products priced via volume discounts and custom projects, achieving fiscal 2024 revenue of approximately $289.9 million driven by synthetic biology (genes and oligo pools representing about 60%), NGS tools (about 35%), and emerging biopharma and data storage segments. Recent developments include the October 2024 royalty purchase agreement with XOMA Royalty Corporation providing $15 million in upfront cash in exchange for half of future milestone and royalty payments from existing antibody discovery collaborations while retaining all service revenue and rights to new biopharma deals; expansion of the Express Genes rapid synthesis service launched in November 2023 to midiprep (10-100 micrograms) and maxiprep (100 micrograms-1 milligram) scales in early 2024 to accelerate large-scale experimentation; and collaborations such as the launch of Trinity Freestyle Fast Hybridization Workflow for Element Biosciences' AVITI sequencing system in late 2025 alongside ongoing NGS ProLab partnerships and channel distributor networks to enhance product accessibility and market penetration in high-growth healthcare and biopharma end markets representing nearly 60% of revenue.
Company News
Twist Bioscience (NASDAQ:TWST) Shares Down 7.4% – Here’s Why
Polen 5Perspectives Small-Mid Growth Q3 2026 Portfolio Update
How to Invest in AI Drug Discovery
These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?
Head to Head Survey: Quantum-Si (NASDAQ:QSI) versus Twist Bioscience (NASDAQ:TWST)
Twist Bioscience (NASDAQ:TWST) Stock Falls 9.7% Following Insider Selling
The Top HealthTech Questions Landing on Our Desks
Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?
3 Analysts, 3 Trades to Make Today
Why Twist Bioscience Stock Skyrocketed This Week
Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
AI & Robotics in 2026: 16 Recent Developments for Investors
Twist Bioscience to Present at Baird 2026 Global Healthcare Conference
Brandywine Managers LLC Invests $2.16 Million in Twist Bioscience Corporation $TWST
90,053 Shares in Twist Bioscience Corporation $TWST Acquired by Deutsche Bank AG
Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)
Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report
The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech)